Want to see CLDX full AI Analyst Report?
CLDX Stock Chart & Stats
$35.28
$0.37(1.05%)
At close: 4:00 PM EDT
$35.28
$0.37(1.05%)
Day’s Range― - ―
52-Week Range$19.72 - $42.92
Previous Close$35.65
Volume1.04M
Average Volume (3M)1.19M
Market Cap
$2.99B
Enterprise Value$1.67K
Total Cash (Recent Filing)$717.59M
Total Debt (Recent Filing)$4.90M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 11, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.36
Shares Outstanding78,492,070
10 Day Avg. Volume933,099
30 Day Avg. Volume1,193,186
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$58.79Price Target Upside66.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.35
Revenue Forecast (FY)$2.21M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetCelldex’s balance sheet shows very low debt and sizable equity, materially reducing solvency and refinancing risk for a capital-intensive biotech. This durable financial flexibility supports multi-year clinical programs and provides runway to fund R&D without immediate operating revenue.
Focused, Late‑stage Mast‑cell PipelineThe company’s concentrated pipeline—including two Phase 3 trials for barzolvolimab and a bispecific candidate CDX-622—represents a structural strength: late‑stage assets reduce development risk versus early programs and create a clear pathway to regulatory and commercial inflection points if trials succeed.
Governance Support And Incentive FlexibilityShareholder approval of an expanded equity incentive plan and re-election of directors signals board and investor alignment. The added authorization gives management a durable tool to retain talent and align incentives through lengthy development cycles, supporting execution continuity.
Bears Say
Accelerating Cash BurnOperating and free cash flows are persistently negative and have accelerated in the trailing twelve months, increasing funding pressure. This structural cash burn raises the probability of near-term financing needs and constrains the firm’s ability to self-fund pivotal trials without external capital.
Near‑zero And Deteriorating RevenueRevenue has fallen to near-zero on a TTM basis and remains volatile, reflecting no commercialized products. This structural lack of recurring revenue limits margin sustainability and forces reliance on non‑operating funding sources to support R&D and eventual commercialization investments.
Dependence On External Financing And Dilution RiskAs a clinical‑stage biotech with rising cash burn and minimal revenue, Celldex will likely rely on additional equity or partner funding. The recently expanded incentive share pool highlights potential dilution as an ongoing structural risk that can erode shareholder value if future financings are required.
Celldex News
CLDX FAQ
What was Celldex Therapeutics’s price range in the past 12 months?
Celldex Therapeutics lowest stock price was $19.72 and its highest was $42.92 in the past 12 months.
What is Celldex Therapeutics’s market cap?
Celldex Therapeutics’s market cap is $2.99B.
When is Celldex Therapeutics’s upcoming earnings report date?
Celldex Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 93 days.
How were Celldex Therapeutics’s earnings last quarter?
Celldex Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.057 by $0.117.
Is Celldex Therapeutics overvalued?
According to Wall Street analysts Celldex Therapeutics’s price is currently Undervalued.
Does Celldex Therapeutics pay dividends?
Celldex Therapeutics does not currently pay dividends.
What is Celldex Therapeutics’s EPS estimate?
Celldex Therapeutics’s EPS estimate is -1.02.
How many shares outstanding does Celldex Therapeutics have?
Celldex Therapeutics has 78,492,070 shares outstanding.
What happened to Celldex Therapeutics’s price movement after its last earnings report?
Celldex Therapeutics reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.057. Following the earnings report the stock price went up 0.361%.
Which hedge fund is a major shareholder of Celldex Therapeutics?
Currently, no hedge funds are holding shares in CLDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celldex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.79 (66.63% Upside)
$58.79 (66.63% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 83.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.99%
Trailing 12-Months
Company Description
Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
CLDX Stock 12 Month Forecast
Average Price Target
$58.79
▲(66.63% Upside)
Technical Analysis
Nektar Therapeutics
―
Iovance Biotherapeutics
―
Nurix Therapeutics
―
Nuvation Bio
―
Immunome
―
Ownership Overview
0.30% Insiders
25.03% Mutual Funds
4.25% Other Institutional Investors
56.04% Public Companies and
Individual Investors